Literature DB >> 2468397

Fenfluramine administered systemically or locally increases extracellular serotonin in the lateral hypothalamus as measured by microdialysis.

D Schwartz1, L Hernandez, B G Hoebel.   

Abstract

Microdialysis was used to monitor serotonin, 5-hydroxyindoleacetic acid (5-HIAA) and the metabolites of dopamine, dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) in the perifornical lateral hypothalamus (PFH) of freely moving rats. Systemically administered d-fenfluramine (d-FEN) increased extracellular serotonin, DOPAC and HVA, while decreasing serotonin's metabolite 5-HIAA. Local application of d-FEN directly to the hypothalamic terminal region caused large increases in extracellular serotonin and had a tendency to decrease all 3 metabolites. This effect was confirmed when d-FEN was infused locally by reverse dialysis. These results provide direct evidence that the anorectic drug d-FEN can increase extracellular serotonin in the hypothalamus in vivo and suggest a serotonergic action in the perifornical region. This finding is consistent with our report that a meal also increases serotonin in this region.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2468397     DOI: 10.1016/0006-8993(89)91189-x

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  15 in total

1.  5-HT modulation of auditory and visual sensorimotor gating: I. Effects of 5-HT releasers on sound and light prepulse inhibition in Wistar rats.

Authors:  J H Kehne; R A Padich; T C McCloskey; V L Taylor; C J Schmidt
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

2.  Effects of fenfluramine and para-chloroamphetamine on sexual behavior of male rats.

Authors:  M M Foreman; J L Hall; R L Love
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

3.  Suppression of behavioral activity by norfenfluramine and related drugs in rats is not mediated by serotonin release.

Authors:  C W Callaway; L L Wing; D E Nichols; M A Geyer
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

4.  Comparative studies on the anorectic activity of d-fenfluramine in mice, rats, and guinea pigs.

Authors:  T Mennini; A Bizzi; S Caccia; A Codegoni; C Fracasso; E Frittoli; G Guiso; I M Padura; C Taddei; A Uslenghi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-05       Impact factor: 3.000

5.  Serotonin2 receptor agonists and serotonergic anorectic drugs affect rats' performance differently in a five-choice serial reaction time task.

Authors:  M Carli; R Samanin
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

Review 6.  Dexfenfluramine. A review of its pharmacological properties and therapeutic potential in obesity.

Authors:  D McTavish; R C Heel
Journal:  Drugs       Date:  1992-05       Impact factor: 9.546

7.  Effect of hypothalamic and peripheral fluoxetine injection on natural patterns of macronutrient intake in the rat.

Authors:  G F Weiss; N Rogacki; A Fueg; D Buchen; J S Suh; D T Wong; S F Leibowitz
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

8.  Serotonergic responses in depressed patients with or without a history of alcohol use disorders and healthy controls.

Authors:  Leo Sher; Barbara H Stanley; Thomas B Cooper; Kevin M Malone; J John Mann; Maria A Oquendo
Journal:  Eur Neuropsychopharmacol       Date:  2008-06-30       Impact factor: 4.600

9.  Functional consequences of central serotonin depletion produced by repeated fenfluramine administration in rats.

Authors:  M H Baumann; M A Ayestas; R B Rothman
Journal:  J Neurosci       Date:  1998-11-01       Impact factor: 6.167

10.  N-methyl-D-aspartate lesions of the lateral hypothalamus do not reduce amphetamine or fenfluramine anorexia but enhance the acquisition of eating in response to tail pinch in the rat.

Authors:  J M Clark; A J Clark; P Winn
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.